159 results
8-K
EX-99.3
TXMD
TherapeuticsMD Inc
12 Nov 21
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer
6:47am
prioritized effort Great team committed to success Significant managed care and other wins 11
Initial Assessment 12
Retarget and redistribute activity … targeting and mix assessment to be completed Q4 2021 20
Accelerators for Q4 and Beyond Significant managed care wins Major sources of Prior
8-K
EX-10.1
TXMD
TherapeuticsMD Inc
2 Mar 12
Departure of Directors or Certain Officers
12:00am
with the CEO to discuss the CEO's self-assessment in achieving individual and corporate performance goals and objectives.
Oversee the evaluation
424B3
fyufc6b1rxggn zl
7 Aug 13
Prospectus supplement
12:00am
CORRESP
u5onh 0vly76
30 Jul 07
Correspondence with SEC
12:00am
CORRESP
4ehjbll63fri66jkh
19 Jul 07
Correspondence with SEC
12:00am
8-K/A
EX-99.1
oonbp6hqzle
16 Nov 21
Results of Operations and Financial Condition
6:30am
424B3
zcpzb opux9m52z2
24 Dec 13
Prospectus supplement
12:00am
8-K
52ig 17qvujl
2 Mar 12
Departure of Directors or Certain Officers
12:00am
424B3
zn9g0enbmqeg9b
5 Nov 13
Prospectus supplement
12:00am
CORRESP
7l0ifdv62ux 6238wbii
5 Jun 07
Correspondence with SEC
12:00am